Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on August 9, 2016. The registrant is a Delaware corporation headquartered in San Diego, California, focused on developing liquid biopsy tests, specifically the Trovera® EGFR urine-based test.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior period are reported in this document. The filing discloses two specific corporate events:
- Publication of a patient case report featuring the Trovera® EGFR test in the journal Experimental Hematology & Oncology.
- Scheduled attendance by the Company at the 2016 Avondale Partners Healthcare 1-1 Conference in Boston, Massachusetts, on August 10, 2016.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. Management commentary is limited to the announcement of the scientific publication and the upcoming conference appearance.
Key Facts for Investor Verification
- Verify the details of the patient case report published in Experimental Hematology & Oncology regarding the Trovera® EGFR test.
- Confirm the Company's participation and any presentations made at the Avondale Partners Healthcare 1-1 Conference.
- Note that the registrant name in the filing is Trovagene, Inc., distinct from the Cardiff Oncology, Inc. name provided in the request metadata.